Perrigo (PRGO) Change in Accured Expenses (2013 - 2026)
Perrigo's (PRGO) quarterly Change in Accured Expenses came in at -$24.9 million in Q1 2026, up 55.61% year-on-year from -$16.0 million in Q1 2025, and down 0.81% on a QoQ basis from -$24.7 million in Q4 2025.
Perrigo (PRGO) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Change in Accured Expenses data on file, last reported at -$24.9 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 55.61% year-over-year to -$24.9 million in Q1 2026; TTM through Mar 2026 was -$32.2 million, a 455.17% decrease from a year earlier, with the FY2025 full-year figure at -$63.4 million, down 4776.92% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$24.9 million, down from -$24.7 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for PRGO reached as high as $55.7 million in Q3 2023 and fell as low as -$66.0 million in Q4 2023.
- Historically, Change in Accured Expenses has averaged -$10.6 million across 5 years, with a median of -$15.1 million in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 3376.47% in 2023 and fell as far as 2969.57% in 2023.
- Year by year, Change in Accured Expenses stood at $2.3 million in 2022, then plunged by 2969.57% to -$66.0 million in 2023, then surged by 64.09% to -$23.7 million in 2024, then declined by 4.22% to -$24.7 million in 2025, then fell by 0.81% to -$24.9 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$24.9 million in Q1 2026, -$24.7 million in Q4 2025, and -$15.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -24.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -24.90 Mn |
| Mar 28, 2026 | -24.90 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Sep 27, 2025 | -15.10 Mn |
| Sep 27, 2025 | -15.10 Mn |
| Jun 28, 2025 | 32.50 Mn |
| Jun 28, 2025 | 32.50 Mn |
| Mar 29, 2025 | -56.10 Mn |
| Mar 29, 2025 | -56.10 Mn |
| Dec 31, 2024 | -23.70 Mn |
| Dec 31, 2024 | -23.70 Mn |
| Sep 28, 2024 | 39.30 Mn |
| Sep 28, 2024 | 39.30 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Mar 30, 2024 | -51.60 Mn |
| Mar 30, 2024 | -51.60 Mn |
| Dec 31, 2023 | -66.00 Mn |
| Dec 31, 2023 | -66.00 Mn |